gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 08 Dec 2016.

Tachykinin receptor 1

neurokinin-1 receptor, NK1 receptor, NK-1R
This gene belongs to a gene family of tachykinin receptors. These tachykinin receptors are characterized by interactions with G proteins and contain seven hydrophobic transmembrane regions. This gene encodes the receptor for the tachykinin substance P, also referred to as neurokinin 1. The encoded protein is also involved in the mediation of phosphatidylinositol metabolism of substance P. [provided by RefSeq, Sep 2008] (from NCBI)
Top mentioned proteins: substance P, CAN, V1a, Neuropeptide, HAD
Papers using neurokinin-1 receptor antibodies
Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis.
Supplier
Ulasov Ilya, In PLoS ONE, 2009
... The NK1R antagonist, aprepitant (Emend®), manufactured by Merck & Co ...
Substance P receptor immunodetection in the spinal cord: comparative use of direct anti-receptor antibody and anti-complementary peptide antibody
Supplier
Atsumi Saoko et al., In Acta Histochemica et Cytochemica, 1997
... After several rinses in PBS, the sections for the NK-1R and tachykinin double-immunolabeling were incubated in biotinylated anti-rabbit IgG (1:200, Vector Laboratories, Burlingame, CA), rinsed and ...
Papers on neurokinin-1 receptor
Aprepitant for antiemesis after laparoscopic gynaecological surgery: A randomised controlled trial.
New
Lee et al., Seoul, South Korea. In Eur J Anaesthesiol, Feb 2016
BACKGROUND: Ondansetron, a 5-HT3 receptor antagonist, and aprepitant, a neurokinin-1 receptor antagonist, block the emetic effect of serotonin and neurokinin, respectively.
Inhibitory Effect of Endomorphin-2 Binding to the μ-Opioid Receptor in the Rat Pre-Bötzinger Complex on the Breathing Activity.
New
Li et al., Xi'an, China. In Mol Neurobiol, Feb 2016
Some EM2-LI axonal terminals made principally symmetric synapses with neurokinin 1 receptor (NK1R)-LI or MOR-LI neuronal dendritic processes in the pre-BötC.
Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics.
New
Ballet et al., Brussels, Belgium. In Acs Med Chem Lett, Jan 2016
Herein, the synthesis and biological evaluation of dual opioid agonists-neurokinin 1 receptor (NK1R) antagonists is described.
Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Review
New
Slusher et al., Baltimore, United States. In Cancer Treat Rev, Dec 2015
These data suggest that delayed emesis can be substantially reduced via combined 5-HT3 and NK1 receptor neurotransmitter pathway inhibition.
Acute versus chronic phase mechanisms in a rat model of CRPS.
New
Clark et al., Palo Alto, United States. In J Neuroinflammation, Dec 2015
However, spinal levels of NK1 receptor, TNFα, IL-1β, and NGF were elevated at 4 and 16 weeks, and intrathecal injection of an NK1-receptor antagonist (LY303870), anakinra, or anti-NGF each reduced nociceptive behaviors at both 4 and 16 weeks.
Antiemetics: American Society of Clinical Oncology Focused Guideline Update.
New
Impact
Kris et al., Burlington, United States. In J Clin Oncol, Dec 2015
RECOMMENDATIONS: All patients who receive highly emetogenic chemotherapy regimens (including anthracycline plus cyclophosphamide) should be offered a three-drug combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone.
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
New
Impact
Schnadig et al., Memphis, United States. In Lancet Oncol, Sep 2015
We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone, for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of moderately emetogenic chemotherapy or regimens containing an anthracycline and cyclophosphamide.
Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials.
Review
New
Verheul et al., Amsterdam, Netherlands. In Support Care Cancer, Aug 2015
The addition of an NK1 receptor antagonist to first-generation 5-HT3 receptor antagonists does not significantly improve the incidence of delayed CINV after non-AC MEC.
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
New
Impact
Zwaan et al., Seoul, South Korea. In Lancet Oncol, Apr 2015
BACKGROUND: Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in combination with other anti-emetic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy in adults, but its efficacy and safety in paediatric patients are unknown.
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Review
Rugo et al., Burlington, United States. In Biomed Res Int, 2014
NEPA is an oral fixed combination of a new highly selective NK1 receptor antagonist (RA), netupitant, and the pharmacologically and clinically distinct 5-HT3 RA, palonosetron.
Biological and Pharmacological Aspects of the NK1-Receptor.
Review
Gascón et al., Barcelona, Spain. In Biomed Res Int, 2014
The neurokinin 1 receptor (NK-1R) is the main receptor for the tachykinin family of peptides.
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Review
Natale, Pittsburgh, United States. In Hosp Pract (minneap), 2014
This review provides background information on chemotherapy-induced nausea and vomiting (CINV) classification and pathophysiology and reviews various antiemetic agents for CINV prophylaxis, including corticosteroids, serotonin receptor antagonists (5-HT3 RAs), tachykinin NK1 receptor antagonists (NK1 RAs), and olanzapine.
Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis.
Philipp et al., United States. In J Neuroinflammation, 2014
The neuropeptide substance P (SP) is an important mediator of both neuroinflammation and blood-brain barrier dysfunction, through its NK1 receptor.
Detection of the full-length transcript variant for neurokinin-1 receptor in human whole blood associated with enhanced reinforcement of clot by substance-P.
GeneRIF
Kikuchi et al., Saitama, Japan. In J Thromb Thrombolysis, 2012
the importance of p31(comet) in checkpoint silencing and its potential as a target for antimitotic therapies.
Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor.
GeneRIF
Benton et al., Philadelphia, United States. In J Neuroimmunol, 2012
Specific inhibition of NK1-R completely blocks tissue factor (substance P) expression.
Increased neurokinin-1 receptor availability in temporal lobe epilepsy: a positron emission tomography study using [(11)C]GR205171.
GeneRIF
Kumlien et al., Uppsala, Sweden. In Epilepsy Res, 2011
Our results suggest that there is an intrinsic network using the NK1-SP receptor system for synaptic transmission and epileptiform activity in temporal lobe epilepsy.
Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.
GeneRIF
Becker et al., Boston, United States. In Proc Natl Acad Sci U S A, 2011
there may be a functional role for truncated-NK-1R in malignant transformation in colitis-associated cancer
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Impact
Herrstedt et al., Burlington, United States. In J Clin Oncol, 2011
PURPOSE: Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours).
NCAM1, TACR1 and NOS genes and temperament: a study on suicide attempters and controls.
GeneRIF
Serretti et al., München, Germany. In Neuropsychobiology, 2010
This study did not support the tacr1 is direct modulation of these genes on temperament
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Impact
Grunberg et al., Copenhagen, Denmark. In J Clin Oncol, 2009
PURPOSE: The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC).
share on facebooktweetadd +1mail to friends